|
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools
Email Alerts
Search Investor Relations
|
Press Releases
All Releases
 |
Pharmasset to Present at Cowen and Company 30th Annual Healthcare Conference
Mar 3, 2010
|
12.2 KB |
|
| |
PRINCETON, N.J., March 3, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Cowen and Company 30th Annual Healthcare Conference being held from March 8 to 11, 2010 at the Boston Copley Marriot Place, Boston, MA. Schaefer Price, Pharmasset's President and Chief Executive Office...
|
|
Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study
Feb 17, 2010
|
11.5 KB |
|
| |
PRINCETON, N.J., Feb 17, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.
Roche...
|
|
Pharmasset Reports Fiscal First Quarter 2010 Financial Results
Feb 9, 2010
|
15.9 KB |
|
| |
PRINCETON, N.J., Feb 09, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended December 31, 2009.
...
|
|
Pharmasset Announces Exercise of Underwriter's Option
Jan 29, 2010
|
9.4 KB |
|
| |
PRINCETON, N.J., Jan 29, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriter of its recent stock offering has exercised its option to purchase an additional 230,400 shares of common stock. The net proceeds to Pharmasset, Inc., after deducting the underwriting discount, from the sale of these...
|
|
Pharmasset Prices Underwritten Offering of Common Stock
Jan 28, 2010
|
9.5 KB |
|
| |
PRINCETON, N.J., Jan 28, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the pricing of an underwritten offering of 1,600,000 shares of its common stock at a price of $18.75. After the underwriting discount and estimated offering expenses, Pharmasset expects to receive net proceeds of approximately $28....
|
|
Pharmasset Announces Proposed Public Offering of Common Stock
Jan 27, 2010
|
10.2 KB |
|
| |
PRINCETON, N.J., Jan 27, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has commenced an underwritten public offering, subject to market and other conditions, of $30,000,000 of its common stock pursuant to effective shelf registration statements. Pharmasset intends to grant to the underwriters ...
|
|
Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851
Jan 21, 2010
|
12.0 KB |
|
| |
PRINCETON, N.J., Jan 21, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate vario...
|
|
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
Jan 8, 2010
|
11.8 KB |
|
| |
PRINCETON, N.J., Jan 08, 2010 /PRNewswire via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 28th Annual JPMorgan Healthcare Conference being held from January 11 to 14, 2010 at the Westin St Francis in San Francisco, CA. Schaefer Price, Pharmasset's President and Chief Executive Officer, will...
|
|
Pharmasset Reports Fiscal Year End 2009 Financial Results
Nov 25, 2009
|
21.5 KB |
|
| |
PRINCETON, N.J., Nov 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2009. At September 30, 2009 Pharma...
|
|
Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Nov 23, 2009
|
12.4 KB |
|
| |
PRINCETON, N.J., Nov 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleosid...
|
|
Pharmasset to Present at Lazard Capital Markets Healthcare Conference
Nov 9, 2009
|
11.1 KB |
|
| |
PRINCETON, N.J., Nov 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Sixth Annual Lazard Capital Markets Healthcare Conference. The conference will be held at the St Regis Hotel in New York City (November 17-19, 2009).
Schaefer Price, Pharmasset's President and Chi...
|
|
INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
Nov 3, 2009
|
17.5 KB |
|
| |
BOSTON, Nov 03, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of ...
|
|
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Nov 1, 2009
|
12.1 KB |
|
| |
PRINCETON, N.J., Nov 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Monday, November 2, 2009 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progr...
|
|
Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
Oct 6, 2009
|
10.9 KB |
|
| |
PRINCETON, N.J., Oct 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-879 is a proprietary nucleotide analog polymera...
|
|
Pharmasset to Present at JMP Securities Healthcare Conference
Oct 1, 2009
|
10.9 KB |
|
| |
PRINCETON, N.J., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the JMP Securities Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City (October 5-6, 2009).
Schaefer Price, Pharmasset's President and Chief Executive Offi...
|
|
Pharmasset to Present at Four Upcoming Investor Conferences
Sep 8, 2009
|
10.9 KB |
|
| |
PRINCETON, N.J., Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Robert W. Baird & Co. Health Care Conference, Morgan Stanley Unplugged Global Healthcare Conference and the UBS Global Life Sciences Conference in New York, NY and the ThinkEquity G6 Conference in...
|
|
Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
Aug 10, 2009
|
16.5 KB |
|
| |
PRINCETON, N.J., Aug 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal quarter ended June 30, 20...
|
|
Pharmasset to Present at Canaccord Adams Conference
Aug 5, 2009
|
10.7 KB |
|
| |
PRINCETON, N.J., Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Canaccord Adams 29(th) Annual Global Growth Conference in Boston, MA.
Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Wednesday, Augu...
|
|
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
Jul 31, 2009
|
13.0 KB |
|
| |
PRINCETON, N.J., July 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhibitor of HCV.
PSI-7851 Phase 1 Multiple Ascending ...
|
|
Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
Jul 7, 2009
|
10.6 KB |
|
| |
PRINCETON, N.J., July 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the nomination of PSI-352938 ("PSI-938") as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is a proprietary nucleotide analog polymera...
|
|
|
= add release to Briefcase |
